fbpx

Etikett: Nanexa

NANEXA: Focus on dual GLP-1 opportunities and the partner projects

Analys, Research

Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much new in...

Read More

NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play

Analys, Research

Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of its activities...

Read More

NANEXA: Raising our LOAs following a review of the projects

Analys, Research

With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials...

Read More

NANEXA: Outcome of rights issue forces an investor-friendly focus on core projects

Analys, Research

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.1%, Nanexa is...

Read More

NANEXA: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal

Analys, Research

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has...

Read More

NANEXA: Capital raise to pursue a broad set of opportunities in 2024 and 2025

Analys, Research

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount. This will...

Read More

NANEXA: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest

Analys, Research

Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum. NEX-20 is set to provide a more...

Read More

NANEXA: Solid progress in development into 2023, with funding needs on the horizon

Analys, Research

After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results from phase I for...

Read More

NANEXA: Validation from Novo Nordisk positions Nanexa for an eventful year ahead

Analys, Research

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two...

Read More

NANEXA: Novo Nordisk deal offers both scientific validation and investor-friendly financing

Analys, Research

The combination of an exclusive evaluation agreement and directed share issue to Novo Nordisk, global leader in diabetes treatment,...

Read More

For new research on growth stocks, sign up to our newsletter